Erasca (ERAS) Non Operating Income (2020 - 2026)
Erasca (ERAS) reported Non Operating Income of $4.5 million for Q1 2026, up 5982.89% on a YoY basis from $73501.2 in Q1 2025, and down 72.99% quarter-over-quarter from $16.6 million in Q4 2025.
Erasca (ERAS) Non Operating Income (2020 - 2026) Analysis & Trends
Erasca has reported Non Operating Income for 7 years, with the latest figure at $4.5 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 5982.89% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $29.2 million (up 27.16% YoY), and the FY2025 full-year result was $16.4 million, down 8.8% from the prior year.
- Non Operating Income for Q1 2026 stood at $4.5 million, down from $16.6 million in the prior quarter.
- The five-year high for Non Operating Income was $18.3 million in Q4 2024, with the low at -$76000.0 in Q1 2025.
- Historically, Non Operating Income has averaged $4.5 million across 5 years, with a median of $3.9 million in 2025.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 8040.43% — and 2025, when it plunged 101.98%.
- Erasca's Non Operating Income stood at $2.8 million in 2022, then surged by 47.49% to $4.2 million in 2023, then surged by 338.5% to $18.3 million in 2024, then decreased by 9.5% to $16.6 million in 2025, then plunged by 72.99% to $4.5 million in 2026.
- The last three Non Operating Income figures came in at $4.5 million (Q1 2026), $16.6 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | 4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.47 Mn |
| Dec 31, 2025 | 16.55 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Jun 30, 2025 | 4.25 Mn |
| Mar 31, 2025 | -76,000.00 |
| Dec 31, 2024 | 18.29 Mn |
| Sep 30, 2024 | 173,000.00 |
| Jun 30, 2024 | 4.58 Mn |
| Mar 31, 2024 | 3.83 Mn |
| Dec 31, 2023 | 4.17 Mn |
| Sep 30, 2023 | 4.30 Mn |
| Jun 30, 2023 | 4.19 Mn |
| Mar 31, 2023 | 3.83 Mn |
| Dec 31, 2022 | 2.83 Mn |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 297,000.00 |
| Mar 31, 2022 | 47,000.00 |
| Dec 31, 2021 | 584,000.00 |
| Sep 30, 2021 | -25,000.00 |
| Jun 30, 2021 | -30,000.00 |